Metformin inhibits mitochondrial complex I, which is essential for energy (ATP) production during aerobic exercise. This inhibition reduces ATP production and increases AMP (adenosine monophosphate) levels, thereby activating AMP-activated protein kinase (AMPK), a key regulator of cellular energy balance. Due to metformin’s pharmacokinetics, its effects on AMPK activation can persist for 6-12 hours and beyond after a single dose and beyond. This prolonged activation of AMPK can suppress mTOR (mechanistic target of rapamycin), a crucial pathway for muscle protein synthesis and recovery.
Given these effects, it seems logical to avoid metformin before and after Zone 3-5 running, HIIT, or strength training. These forms of exercise rely on ATP production from glycolysis and oxidative phosphorylation, and mTOR activation is essential for muscle repair, hypertrophy, and adaptation. Metformin’s sustained activation of AMPK can blunt these critical adaptations.
However, I have a speculative hypothesis regarding Zone 2 cardio. Unlike Zone 3-5 running or resistance training, Zone 2 cardio relies primarily on the aerobic system for energy production. In this case, the goal is not to drive mTOR-mediated hypertrophy but rather to increase mitochondrial density, improve metabolic flexibility, and enhance fat oxidation. The primary adaptation to Zone 2 cardio is driven by PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), which is stimulated by AMPK activation.
Here’s where metformin might help:
-
AMPK Synergy: Since Zone 2 cardio naturally depletes ATP (converting it to AMP), it already activates AMPK. Metformin’s ability to inhibit mitochondrial complex I further amplifies this signal, leading to a stronger AMPK cascade.
-
PGC-1α and Mitochondrial Biogenesis: Activation of AMPK enhances PGC-1α activity, promoting mitochondrial biogenesis, which is the primary goal of Zone 2 cardio. In this context, metformin might act as a synergistic amplifier of this effect.
-
Reduced Need for mTOR in Recovery: Unlike strength training or HIIT, Zone 2 cardio causes minimal muscle damage and does not require significant mTOR-driven muscle protein synthesis for recovery. Instead, the key goal is mitochondrial adaptation, which is facilitated by AMPK and PGC-1α. Since mTOR activation is less critical for Zone 2 recovery, metformin’s impact on mTOR suppression is less relevant.
Possible Downsides of Metformin During Zone 2 Cardio
-
Reduced Exercise Capacity: By inhibiting mitochondrial complex I, metformin may reduce ATP production and increase reliance on anaerobic metabolism, leading to early fatigue. While this could increase perceived effort, it may also enhance metabolic stress that drives beneficial adaptations like increased mitochondrial biogenesis.
-
Blunted VO2 Max Gains: Some studies have shown that metformin blunts improvements in VO2 max during aerobic training, particularly for higher-intensity cardio. However, for low-intensity Zone 2 cardio, the effect may be less pronounced since VO2 max is not the primary adaptation goal.
Conclusion The idea of taking metformin before Zone 2 cardio may have merit. Since mTOR is not essential for Zone 2 recovery, the inhibition caused by metformin is less of a concern. In contrast, the combined activation of AMPK and PGC-1α may actually enhance mitochondrial biogenesis and fat oxidation.
It is clear, that my reasoning is purely theoretical and supported only by indirect evidence.
Any argumented critiques is highly welcome!